MaaT Pharma AGM strengthens funding authority as MaaT013 faces September regulatory test
MaaT Pharma shareholders have preserved the biotechnology firm’s ability to raise capital as MaaT013 enters a decisive regulatory re-examination and its operating cash runway narrows.
